NurExone - From acute injury to functional recovery NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue By loading exosomes with therapeutic compounds, nanodrugs are created having natural regenerative properties and therapeutic impact
2025-06-20 | NurExone Advances U. S. Growth Strategy with Acceptance . . . TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone CloseCurlyDoubleQuote; or the “Company CloseCurlyDoubleQuote;), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH CloseCurlyDoubleQuote
NurExone Biologic To Regenerate Nerve Cell Damage - MedicalExpo e-Magazine Israeli biopharmaceutical firm NurExone Biologic is aiming to change that Its ExoTherapy platform harnesses the healing potential of exosomes—tiny, naturally occurring vesicles that act as cellular messengers, carrying proteins, RNA, and other molecular signals
Company - NurExone Information Technology; Description NurExone Biologic Inc is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange (TSXV:NRX), the OTCQB Venture Market (OTCQB:NRXBF) and Frankfurt Stock Exchange (FSE:J90) Developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs
Nurexone Announces Acute Spinal Cord Injury Trial ExoPTEN utilizes mesenchymal stem cell-derived exosomes loaded with siRNA targeting PTEN, a molecule that inhibits neural regeneration Preclinical studies in rat models have shown promising results in motor, sensory, and structural recovery after complete spinal cord transection and compression
NurExone Joins Elite Boston Biotech Accelerator for US Market Expansion . . . NurExone Biologic Inc (NRXBF) ha sido aceptada en el prestigioso programa HealthTech Hub Accelerator en Boston, operado por ARMI y Mass General Brigham Esta estrategia respalda la expansión de NurExone en Estados Unidos tras la creación de Exo-top Inc , su filial estadounidense para la fabricación de exosomas conforme a GMP